Robbie Stephens Downgrades Inhale

Analyst Roberts Hazlett says the delay of Inhale's new drug launch -- and the safety concerns surrounding it -- could impact profits

Roberstons Stephens downgraded Inhale Therapeutic (INHL ) to market perform from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.